This company listing is no longer active
ESAL.Y Stock Overview
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 4/6 |
Past Performance | 1/6 |
Financial Health | 5/6 |
Dividends | 3/6 |
Eisai Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥61.51 |
52 Week High | JP¥73.90 |
52 Week Low | JP¥36.88 |
Beta | 0.21 |
1 Month Change | -7.24% |
3 Month Change | 2.28% |
1 Year Change | 19.69% |
3 Year Change | -28.69% |
5 Year Change | 9.25% |
Change since IPO | 208.81% |
Recent News & Updates
Recent updates
Shareholder Returns
ESAL.Y | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -4.4% | -1.4% | -3.2% |
1Y | 19.7% | 9.7% | 19.3% |
Return vs Industry: ESAL.Y exceeded the US Pharmaceuticals industry which returned 3.2% over the past year.
Return vs Market: ESAL.Y exceeded the US Market which returned -12.5% over the past year.
Price Volatility
ESAL.Y volatility | |
---|---|
ESAL.Y Average Weekly Movement | 5.7% |
Pharmaceuticals Industry Average Movement | 9.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.5% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ESAL.Y has not had significant price volatility in the past 3 months.
Volatility Over Time: ESAL.Y's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1941 | 11,322 | Haruo Naito | www.eisai.co.jp |
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer’s disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma.
Eisai Co., Ltd. Fundamentals Summary
ESAL.Y fundamental statistics | |
---|---|
Market cap | US$17.66b |
Earnings (TTM) | US$247.68m |
Revenue (TTM) | US$5.78b |
71.3x
P/E Ratio3.1x
P/S RatioIs ESAL.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ESAL.Y income statement (TTM) | |
---|---|
Revenue | JP¥752.50b |
Cost of Revenue | JP¥187.50b |
Gross Profit | JP¥565.00b |
Other Expenses | JP¥532.77b |
Earnings | JP¥32.23b |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Feb 06, 2023
Earnings per share (EPS) | 112.35 |
Gross Margin | 75.08% |
Net Profit Margin | 4.28% |
Debt/Equity Ratio | 11.2% |
How did ESAL.Y perform over the long term?
See historical performance and comparison